AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04633083 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Data collection
Description: Clinical Data: Registration of patient identity, sex and birth year, Body Mass Index, generic score EQ-5D-3L, Tampa Schaal voor kinesofobia and shoulder specific score like Constant Score, PROMS, ADLER, SST and postoperative ROM.~Imaging Data: A preoperative and postoperative CT scan and 1-year postoperative radiograph (all three part of standard clinical practice) will be obtained. This data is used to extract the bone geometries and implant position.~Movement Analysis: The subject should stand still followed by different motion tasks in the gait lab with collection of shoulder girdle kinematics and kinetics using a 14-camera VICON System.~Stereo Radiographic EOS Measurements: Every subject included in the study will undergo a stereo radiographic EOS exam while quite standing with their arm in various positions (van Andel et al., 2008) .~ROM simulation: With the developed ROM software, we will simulate the ROM of the 2 patient groups based on the available CT scan data.
Study NCT03991624 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Inhibition evaluation
Description: * Stroop Victoria : This test consists of 3 sheets of 24 items, organized in 6 lines of 4 (points, neutral words or names of colours), from which the subject must identify the ink of the stimuli as quickly and precisely as possible.~* Stop Signal task on the computer to give a response to the presentation of a target stimulus (Go signal) (e.g. pressing a button when a red circle appears on the screen, but doing nothing when a blue triangle appears), and prevent this response when the stimulus is followed or preceded by a beep (stop signal) (e.g. the appearance of a red circle is immediately preceded or followed by a beep, the subject should not press the button).
Study NCT03991624 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of mental flexibility
Description: * a letter-number pair task. The subject sees 4 blocks of 48 letter-number pairs appear successively on a screen. When the pair appears at the top, the subject must make a parity judgment but when the pair appears at the bottom, the subject must make a consonant / vowel judgment.~* a category change task, which consists in classifying a word according to one category or another according to a visual clue that appears. The task consists of 4 blocks of 48 stimuli.
Study NCT03991624 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the update
Description: * an update span task for which letters appear on a screen sequentially, and subjects must memorize the last three, without knowing the length of the list. The task will consist of 3 tests of training and then 20 tests. After three errors consecutive, the task ends.~* an n-back task that consists of a sequential presentation of letters, during which the subject must indicate when the stimulus. The task consists of 3 levels, with n = 1, n= 2 or n = 3. For level 1 (with n = 1), the subject must press a button when the same letter appears twice in a row on the screen. This task consists of 75 letters.
Study NCT03991624 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: working memory
Description: * the empan baba task, which mainly involves maintaining information, and which consists in retaining a series of letters, appearing sequentially on a screen, and whose latency time between two word presentations is required for a secondary task: the repetition of baba syllables.~* the task of reading operations which consists in recalling operations series of letters whose presentation is interspersed with the reading aloud of simple operations and of their results.~* the ongoing operational task of recalling a list of letters, the presentation of which is interspersed with operations that are simple to read aloud and to to solve head-on.
Study NCT03991624 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: episodic memory
Description: - A recognition task with a Remember/Know paradigm
Study NCT03075436 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: The comparison group will receive the current standard of care, including potential implementation of government-led policies and programs.
Study NCT01975831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab was administered as an intravenous (IV) infusion over 60 (± 5) minutes.
Study NCT02627638 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ostheopathic treatment
Description: Once their clinical data were collected and their symptoms were assessed, all the enrolled patients had an osteopathic session a week during two weeks. After those sessions, they had an interview (scheduled between D11 and D14) with a psychologist
Study NCT02557165 — intervention group
Intervention type: PROCEDURE
Intervention: Muscle biopsies
Description: Muscle biopsies will allow acces to samples for observational studies. Vastus latetalis: needle biopsy (Bergstrom technique). Diaphragm: open biopsy performed by thoracic surgeon during lung surgery.
Study NCT03118895 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFreedom™ BA9™ drug-coated stent
Description: Drug-coated stent for coronary arteries
Study NCT01431547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: For Part 1: dalotuzumab, intravenously (IV) over 60 minutes every three weeks, dose based on participant body surface area (BSA), starting dose of 900 mg/m\^2, and escalated for successive cohorts of participants until MTD is found
Study NCT02355379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU2 or capectitabine
Study NCT02355379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4 or XELOX
Study NCT01431547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: For Part 2: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, starting at the lowest tolerated dose that met PK target levels in Part 1. For Part 3: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
Study NCT01431547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: For Part 2: ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at 1 dose level lower than the MTD or highest dose level used in the companion study MK-8669-056. For Part 3:ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
Study NCT01043029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: Aleglitazar 150 mcg po daily for 52 weeks
Study NCT01043029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: Pioglitazone 45 mg po daily for 52 weeks
Study NCT02197988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel 1.33% (20ml Volume)
Description: Transversus Abdominis Plane Block
Study NCT02197988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.125% bupivicaine with 2 mcg/ml Fentanyl.
Description: Thoracic Epidural Anesthesia
Study NCT02999360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language therapy
Description: There will be three blocks of treatment, ideally three times a week 100 minutes per day. Treatment will target impairment-directed speech language therapy (SLT) approaches or compensatory-directed SLT in each of the three treatment blocks. Half of the participants will receive the impairment-directed SLT. Half of the participants, will receive treatment that will target compensatory-directed speech language therapy approaches that are focused on functional communication skills in the conversational context. Methods of treatment will include PACE (Promoting Aphasics Communicative Effectiveness (Davis, 2005), conversational coaching (Hopper et al., 2002), and supported conversation (Kagan et al., 2001). The clinician will model and encourage all (verbal and non verbal) modalities of communication.
Study NCT02999360 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Language therapy
Description: There will be three blocks of treatment, ideally three times a week 100 minutes per day. Treatment will target impairment-directed speech language therapy (SLT) approaches or compensatory-directed SLT in each of the three treatment blocks. Half of the participants will receive the impairment-directed SLT. Half of the participants, will receive treatment that will target compensatory-directed speech language therapy approaches that are focused on functional communication skills in the conversational context. Methods of treatment will include PACE (Promoting Aphasics Communicative Effectiveness (Davis, 2005), conversational coaching (Hopper et al., 2002), and supported conversation (Kagan et al., 2001). The clinician will model and encourage all (verbal and non verbal) modalities of communication.
Study NCT02355379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Study NCT02355379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU2 or capecitabine
Study NCT02999360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Background Music
Description: 30 minutes background music only
Study NCT03670862 — intervention group
Intervention type: OTHER
Intervention: CT
Description: Non-contrast computed tomography , computed tomography angiography, computed tomography perfusion imaging
Study NCT03921229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-coaching
Description: Patients will meet with a tele-coach, who is a care team member, via video-calling, on a regular basis for six months to identify and address treatment adherence concern(s).
Study NCT01784549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin Docetaxel Gefitinib Pemetrexed Vinorelbine Gemcitabine
Study NCT02999360 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Background Music
Description: 30 minutes background music only
Study NCT02999360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: There will be three blocks of treatment and the AE will take place for all participants during one or two treatment blocks (randomly assigned), threetimes a week (sessions are three times a week prior to speech therapy but may be one or two times a week if a session is missed or may be up to four or five times a week if one or two sessions are missed and rescheduled due to weather or other circumstances).
Study NCT02999360 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: There will be three blocks of treatment and the AE will take place for all participants during one or two treatment blocks (randomly assigned), threetimes a week (sessions are three times a week prior to speech therapy but may be one or two times a week if a session is missed or may be up to four or five times a week if one or two sessions are missed and rescheduled due to weather or other circumstances).
Study NCT03249558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
Study NCT03249558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
Study NCT03249558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
Study NCT03249558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Description: Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
Study NCT03249558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
Study NCT01784549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Docetaxel Gefitinib Pemetrexed Vinorelbine Gemcitabine
Study NCT00759473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine (DCS)
Description: 50 mg d-cycloserine or placebo taken orally
Study NCT00759473 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: D-Cycloserine (DCS)
Description: 50 mg d-cycloserine or placebo taken orally
Study NCT03927846 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse-guided Web-based Cognitive Behavioral Therapy
Description: nurse contact is to support and enhance participants' motivation to engage in the web-based CBT program.
Study NCT03680131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB01 Cream Placebo
Description: Vehicle Cream containing 0% EB w/w applied BID
Study NCT03680131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB01 Cream 0.2%
Description: EB01 Cream containing 0.2% EB01 w/w applied BID
Study NCT03680131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EB01 Cream 1.0%
Description: EB01 Cream containing 1.0% EB01 w/w applied BID
Study NCT00759473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT00759473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03344497 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: VC Group
Description: VC (Conventional Consultation/Video) Group
Study NCT03687034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Standard-of-care chemotherapy for patients with glioblastoma includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body- surface area per day, seven days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle).
Study NCT03687034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune
Description: Standard-of-care treatment for glioblastoma includes alternating electric-field therapy, or Optune, as a Category 1 treatment in conjunction with temozolomide after maximal safe resection and completion of radiation therapy.
Study NCT02760407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olokizumab 64mg q4w
Description: 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
Study NCT02760407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olokizumab 64mg q2w
Description: 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
Study NCT02760407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab 40mg q2w
Description: 0.4 or 0.8 mL prefilled, single-dose syringe
Study NCT02760407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo q2w
Description: sodium chloride 0.9% solution supplied in either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
Study NCT02760407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo q2w
Description: sodium chloride 0.9% solution supplied in either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule
Study NCT01112215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Initial dose of 2-2.5 mg/kg (according to TMTP levels) for 6 months according the severity of the flare with progressive tapering if complete remission has been obtained
Study NCT01112215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric-Coated Mycophenolate Sodium
Description: Initial dose of 1440 mg/day for 6 months to be tapered progressively if complete remission had been obtained
Study NCT00060086 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pomegranate juice
Description: Subjects receive oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.
Study NCT00323258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Letter to physician/discharge summary
Description: A letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations.
Study NCT00323258 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Letter to physician/discharge summary
Description: A letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations.
Study NCT03958812 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating tumor cells, Volatile organic compounds
Description: Alveolar exhaled breath samples and peripheral venous blood(10ml) will be collected from each patients
Study NCT02095613 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional food
Study NCT02095613 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: food that is nutrient dense
Study NCT00031707 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: eicosapentaenoic acid
Study NCT00031707 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: eicosapentaenoic acid
Study NCT00031707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: megestrol acetate
Study NCT00031707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: megestrol acetate
Study NCT00031707 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study NCT03341013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 Formulation 2
Description: Sequence 1 Period 1 and Sequence 2 Period 2.
Study NCT03341013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 Formulation 3
Description: Sequence 1 Period 2 and Sequence 2 Period 1
Study NCT01715077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab at 3 mg/kg dose
Study NCT01732562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient e-Learning educational tool
Description: Web based site with videos of TKR surgical animation, demonstrations of exercises and activities following surgery and conversations with surgeons, physiotherapist, occupational therapist and patients.
Study NCT03956420 — intervention group
Intervention type: BEHAVIORAL
Intervention: Premedication visit
Description: detailed information about surgery, anaesthesia and postoperative period
Study NCT03956420 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Preoperative period
Description: avoidance of prolonged fasting, intake of fluids with carbohydrates before surgery
Study NCT03956420 — intervention group
Intervention type: DRUG
Intervention: Preoperative period
Description: administration of melatonin 5 mg in the evening and pregabalin 75 mg one hour before entering the operating theatre
Study NCT03956420 — intervention group
Intervention type: OTHER
Intervention: Postoperative period
Description: Fluids 1 ml/kg/h; Discontinuation of propofol at the moment of drainage and cardiovascular system stabilization; Fluids administered orally 2 hours after extubation; Early mobilisation
Study NCT03956420 — intervention group
Intervention type: OTHER
Intervention: Intraoperative period
Description: deep temperature (necessity to maintain normothermia during the stay in the operating theatre 36 °C. Normothermia should be maintained rather than restored.
Study NCT03956420 — intervention group
Intervention type: DRUG
Intervention: Intraoperative period
Description: Pyralgin 1 g i.v. after induction of anaesthesia; in patients allergic to Pyralginum, Perfalgan 1 g i.v.
Study NCT03956420 — intervention group
Intervention type: DRUG
Intervention: Intraoperative period
Description: Ketamine 30 mg i.v. after induction of anaesthesia
Study NCT03956420 — intervention group
Intervention type: DRUG
Intervention: Intraoperative period
Description: Sevoflurane 1.5 MAC higher in patients \< 60 years old
Study NCT03956420 — intervention group
Intervention type: DRUG
Intervention: Intraoperative period
Description: Propofol infusion in patients at risk of postoperative vomiting (Apfel ≥ 2 points), sevoflurane administration at the moments of strong stimuli from the operating field
Study NCT03956420 — intervention group
Intervention type: DRUG
Intervention: Intraoperative period
Description: Continuous infusion of balanced multi-electrolyte fluids 1-3 ml/kg/h
Study NCT00841659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine HCl
Description: 40 mg Film-Coated Tablet
Study NCT00841659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxil®
Description: 40 mg Film-Coated Tablet